Here we cross-referenced the latest insider transactions with the Street’s outlook. In other words, all the three stocks covered below have seen big insider buying, and hold a ‘Strong Buy’ consensus from the Street.

Let’s see why these 3 stocks are buzzing right now:

1. Kratos Defense (Nasdaq:KTOS)

First up: specialized national security company Kratos Defense & Security Solutions. This is a great- and cheap- way to get exposure to the booming drone industry. Indeed, the company is experiencing huge growth in its drone segment, known as UAS.

Just six days ago, director and owner Bandel Carano snapped up shares worth $127,000. This takes his total KTOS holding to just over $177 million. And as we can from the KTOS insider page, his transaction is the latest in a string of insider purchases.

(Click on image to enlarge)

As for the Street, the outlook is bullish. ln the last three months four analysts have published buy ratings on the stock. This is versus just 1 hold rating. These analysts are predicting (on average) 24% upside potential from current levels.

“The growth potential is very strong for the company over the next 3-5 years” writes Noble Financial’s Ben Klieve (Profile & Recommendations). He has a $20 price target on the stock (57% upside potential).

“We believe Kratos is creating meaningful value in excess of current share prices, and believe the rapid growth projected from the UAS segment should justify a higher stock valuation” the analyst states. See what other Top Analysts are saying about KTOS.

2. BeiGene Ltd (Nasdaq:BGNE)

One of the China’s largest biopharmas is BeiGene Ltd. The company is making a name for itself with cutting-edge cancer treatments. Primarily these treatments, known as BTK inhibitors, can shrink or eliminate some B cell tumors by disrupting the BCR pathway.

And now director and owner Baker Bros has made a massive share purchase worth almost $628 million. This five-star insider now holds a $2.8 billion position in the company.

Top Maxim Group analyst Jason McCarthy (Profile & Recommendations) is very encouraged by recent clinical data for the drug Zanubrutinib. He writes “BeiGene remains on track to file two NDAs [new drug applications] this year. We believe the data continues to be highly encouraging for the BTK inhibitor and we see multiple catalysts ahead across the PTK, PD1 and PARP that should, if positive push valuation higher.”

Most encouragingly, he is clear that more upside potential lies ahead. BeiGene’s valuation has risen significantly over the last year, at around ~$9B. However, McCarthy believes that “With a BTK, PD1, PARP and a pipeline of assets, as well as a partner in Celgene and a foothold on the China oncology market, we see more upside in BGNE shares.”

Indeed, McCarthy’s $215 price target indicates big upside potential of 35%. He is one of three analysts that have published recent BeiGene buy ratings. See what other Top Analysts are saying about BGNE.

3. Strongbridge Biopharma (Nasdaq:SBBP)

Rare disease biopharma Strongbridge now has two commercial rare disease assets: Keveyis (PPP) and Macrilen (AGHD). Recorlev comes close behind in pivotal Phase 3 studies for Cushing’s syndrome.

We can see from the Insider Hot Stocks tool that owner CDK Associates has been busy ramping up its SBBP holding. Following the most recent $1.7 million transaction, CDK now owns $37 million of Strongbridge shares.

(Click on image to enlarge)

Luckily for CDK, the Street is also displaying a positive sentiment on SBBP’s outlook. Top-rated Oppenheimer anlayst Hartaj Singh (Profile & Recommendations) has just ramped up his price target from $12 to $15. Given current share levels, this suggests 150% upside potential.

According to Singh, “The ability of the highly focused, strategic and experienced management team to scale the Keveyis and Macrilen revenues while preparing for Recorlev launch by late 2019E/early 2020E is key to significantly re-rating the company. We believe management is poised to execute on this strategy, and we are bullish on the story.”